Attention%20deficit_hyperactivity%20disorder Management

Management

Follow Up

Initially, monitor on a monthly basis until consistent optimal response is noted
- Then every 3 months in the 1st year of treatment

Subsequent follow-up will depend on patient’s response, adherence to treatment strategy, presence of associated conditions
- Recommended is at least 2 times a year

Monitor treatment outcomes and adverse effects (cardiovascular effects, development of tics or seizures, sexual dysfunction, changes in sleep pattern, worsening behavior, stimulant misuse and diversion) by gathering information from parents, teachers and the child
Monitor core symptoms using DSM-5-based ADHD rating scales (eg Vanderbilt ADHD follow-up scales)
Re-evaluate the patient when treatment and management plan does not meet desired outcomes
Reassess patient at school-leaving age to check for continuity of care into adulthood

NCDs in Focus Act Now! Summit 2022

16 Mar 2023

Viatris, a global healthcare company, collaborated with the Thai Hypertension Society and the Thai NCD Collaboration Group to organize the NCDs in Focus Act Now! Summit 2022 in Bangkok on October 29^th and 30^th. This summit brought together nearly 300 multidisciplinary experts from Southeast Asia and India to address the unmet needs in managing two critical noncommunicable diseases (NCDs): cardiovascular diseases (CVDs) and mental health disorders (MHDs) in the region.

The summit had several key objectives. Firstly, it highlighted the effectiveness of clinical data in addressing gaps and unmet needs in clinical practice. Secondly, it emphasized the importance of sharing expertise and best practices through a platform that can optimize patient care. Additionally, it discussed the challenges of cardiovascular disease and mental health disorder care in a post COVID-19 world, and the need to re-examine them.

The summit also offered valuable insights into policy and practice changes, as well as innovative digital solutions that can lead to better outcomes. Lastly, it emphasized the significance of gaining a deeper understanding of the gaps in the patient journey to enhance patient care further.

Overall, the NCDs in Focus Act Now! Summit 2022 was a highly informative and productive event, with experts collaborating to improve the management of CVDs and MHDs in Southeast Asia and India.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.